C12N 2501/2302
Interleukin-2
Official title: Interleukin-2 (IL-2)
C12N2501/2302 (Interleukin-2) appears on 563 US grants and 1,523 published applications in this corpus.
Search patents in C12N- Granted patents
- 563
- Published applications
- 1,523
- Assignees
- 627
- Inventors
- 2,661
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 2 |
| 2004 | 0 | 1 |
| 2005 | 1 | 0 |
| 2006 | 1 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 1 |
| 2009 | 1 | 4 |
| 2010 | 4 | 7 |
| 2011 | 1 | 14 |
| 2012 | 4 | 17 |
| 2013 | 4 | 23 |
| 2014 | 9 | 22 |
| 2015 | 19 | 32 |
| 2016 | 13 | 30 |
| 2017 | 19 | 59 |
| 2018 | 22 | 68 |
| 2019 | 32 | 94 |
| 2020 | 35 | 100 |
| 2021 | 69 | 177 |
| 2022 | 57 | 205 |
| 2023 | 50 | 174 |
| 2024 | 74 | 193 |
| 2025 | 76 | 181 |
| 2026 | 68 | 115 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- K562 universal antigen presenting cells and uses thereof15 Sep 2026US 12,734,239 B2Board of Regents, The University of Texas System
- T cell receptors recognizing R273C or Y220C mutations in P531 Sep 2026US 12,721,890 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Media and methods for differentiating natural killer cells1 Sep 2026US 12,723,233 B2Stemcell Technologies Canada Inc.
- Methods of preparing anti-human papillomavirus antigen T cells11 Aug 2026US 12,702,706 B2The United States of America, as represented by the Secretary, Department of Health and Human Seervices
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy1 Oct 2026US 2026/0293881 A1Iovance Biotherapeutics, Inc.
- Enrichment and expansion of chimeric antigen receptor t cells using antigen-presenting biomaterials1 Oct 2026US 2026/0297520 A1The Regents of the University of California
- Populations of enriched regulatory t cells and methods for producing same1 Oct 2026US 2026/0297523 A1Cellenkos, Inc.
Most cited
By later US patents
- Handheld electromechanical surgical system627US 10,932,784 B2Covidien LP · 2021
- Methods of cell culture for adoptive cell therapy156US 8,956,860 B22015
- Artificial antigen presenting cells and uses therefor105US 7,754,482 B2The Trustees of the University of Pennsylvania · 2010
- Method of culturing lymphocytes and method of treatment using such lymphocytes88US 5,443,983 ARegents of the University of Minnesota · 1995
- Artificial antigen presenting cells and uses therefor76US 8,722,400 B2The Trustees of the University of Pennsylvania · 2014